Rocklatan (latanoprost/netarsudil) / Alcon - LARVOL DELTA

Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost (clinicaltrials.gov) - P4 | N=70 | Not yet recruiting | Sponsor: Prairie Eye Center

New P4 trial • Glaucoma • Ophthalmology

Improved Efficacy of Selective Laser Trabeculoplasty With the Addition of Rocklatan Post-treatment vs Artificial Tears Post-treatment (clinicaltrials.gov) - P=N/A | N=70 | Recruiting | Sponsor: Colorado Ophthalmology Associates PC | Not yet recruiting ➔ Recruiting

Enrollment open • Glaucoma • Ophthalmology

Improved Efficacy of Selective Laser Trabeculoplasty With the Addition of Rocklatan Post-treatment vs Artificial Tears Post-treatment (clinicaltrials.gov) - P=N/A | N=70 | Not yet recruiting | Sponsor: Colorado Ophthalmology Associates PC

New trial • Glaucoma • Ophthalmology

netarsudil plus latanoprost (Roclanda) is accepted for restricted use within NHSScotland (Scottish Medicines Consortium) - "Indication under review: for the reduction of elevated intraocular pressure (IOP) in adult patients with primary open-angle glaucoma or ocular hypertension for whom monotherapy with a prostaglandin or netarsudil provides insufficient IOP reduction. SMC restriction: for use in patients for whom treatment with a prostaglandin analogue alone provides insufficient IOP reduction, only if: the patient has then tried a fixed-dose combination treatment and it has not sufficiently reduced IOP, or a fixed-dose combination treatment containing beta-blockers is unsuitable."

Reimbursement • Glaucoma • Ophthalmology

Effects of Switching to Netarsudil/Latanoprost Fixed Dose Combination from Various Latanoprost Regimens: The Phase 4 MORE Study. (PubMed, Clin Ophthalmol) - "In this study, additional IOP lowering was achievable when patients switched to netarsudil/latanoprost FDC after treatment with latanoprost alone or latanoprost with 1 or 2 additional agents. The once-daily administration of netarsudil/latanoprost FDC and reduced treatment burden for those on latanoprost combined with additional agents may prove more manageable for patients."

Clinical • Journal • P4 data • Cardiovascular • Glaucoma • Ophthalmology

GLR305-E001: Next Generation Rocklatan (clinicaltrials.gov) - P2 | N=450 | Recruiting | Sponsor: Alcon Research | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Glaucoma • Ophthalmology

Next Generation Rocklatan (clinicaltrials.gov) - P2 | N=450 | Not yet recruiting | Sponsor: Alcon Research

New P2 trial • Cardiovascular • Glaucoma • Ophthalmology

Rocklatan Could Raise Hopes For Glaucoma Patients. (ESCRS 2023) - "ROCKLATAN with once-daily dosing, has shown to be more effective than using either netarsudil or latanoprost alone. This combination has the potential to decrease the treatment burden and improve adherence and clinical outcomes for patients with open-angle glaucoma or ocular hypertension."

Clinical • Glaucoma • Ophthalmology

Mercury-3 Exploratory Analyses: Netarsudil/Latanoprost Efficacy And Tolerability Stratified By Prior Prostaglandin Use In Patients With Glaucoma And Ocular Hypertension. (ESCRS 2023) - "The exploratory analysis of MERCURY-3 demonstrated that the IOP-reducing efficacy of NET/LAT was consistent whether a patient had received prior PGA (either as monotherapy or in combination) or not. The corresponding hyperaemia frequency figures for patients with/without prior PGA therapy were similar in the NET/LAT and BIM/TIM arms. These findings can help physicians to make informed decisions on treatment initiation for optimized management of glaucoma and ocular hypertension."

Clinical • Glaucoma • Ophthalmology

MERCURY-3: a randomized comparison of netarsudil/latanoprost and bimatoprost/timolol in open-angle glaucoma and ocular hypertension. (PubMed, Graefes Arch Clin Exp Ophthalmol) - "Once-daily NET/LAT was non-inferior to BIM/TIM in IOP reduction in OAG and OHT, with AEs consistent with previous findings. NET/LAT offers a compelling alternative FDC treatment option for OAG and OHT."

Journal • Cardiovascular • Glaucoma • Ophthalmology

Managing primary open-angle glaucoma in the setting of suboptimal surgical outcomes in the fellow eye. (PubMed, J Cataract Refract Surg) - "The addition of acetazolamide lowered the pressure to 19 mm Hg in both eyes, but she tolerated it poorly...However, by postoperative week 3, IOP returned to 27 mm Hg, and despite restarting latanoprost-netarsudil and finishing her steroid taper, IOP remained at 27 mm Hg by postoperative week 6...Knowing her postoperative course in the left eye, how would you manage the right eye? In addition to currently available options, would you consider a supraciliary shunt such as the MINIject (iSTAR) if such a device were U.S. Food and Drug Administration (FDA)-approved?"

Journal • Cataract • Glaucoma • Ophthalmology

"rhopressa, rocklatan" (@YichengB)

Rho-kinase Inhibitors in Ocular Diseases: A Translational Research Journey. (PubMed, J Curr Glaucoma Pract) - "While the Rho Kinase Elevated intraocular Pressure (IOP) Treatment (ROCKET) trials compared monotherapy with ROCK inhibitor netarsudil vs timolol, MERCURY trials compared a fixed dose combination of latanoprost and ROCK inhibitor netarsudil [fixed combination netarsudil-latanoprost (FCNL)] vs monotherapy with either and bimatoprost-timolol combination. Singh K, Singh A. Rho-kinase Inhibitors in Ocular Diseases: A Translational Research Journey. J Curr Glaucoma Pract 2023;17(1):44-48."

Journal • Review • Colorectal Cancer • Diabetic Retinopathy • Gastrointestinal Cancer • Glaucoma • Oncology • Ophthalmology • Rectal Cancer • Retinal Disorders • Solid Tumor

Rocklatan® Evaluation (clinicaltrials.gov) - P4 | N=136 | Completed | Sponsor: Aerie Pharmaceuticals | Active, not recruiting ➔ Completed

Trial completion • Cardiovascular • Glaucoma • Ophthalmology

Improved glaucoma medication access through pharmacy partnership to minimize out-of-pocket costs: A single institution experience (ARVO 2023) - "Of the 343 inquiries, 211 were for Rocklatan; initial responses were 125 covered, 81 not on formulary, and 8 requiring prior authorizations...Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."

Clinical • Licensing / partnership • Glaucoma • Ophthalmology

ROCK (RHO-KINASE INHIBITORS) FOR THE TREATMENT OF OPEN-ANGLE GLAUCOMA AND OCULAR HYPERTENSION (PubMed, Harefuah) - "The efficacy and safety of the drug were studied in the ROCKET and MERCURY clinical trials, in which Netarsudil was compared to other common drugs, including Timolol (Beta-blocker), Latanoprost (Prostaglandin analog), and a combination drop containing Netarsudil and Latanoprost. The most common adverse event reported was conjunctival hyperemia, which was more frequent in patients using Netarsudil. However, this did not significantly affect the drug tolerance."

Journal • Cardiovascular • Glaucoma • Ophthalmology

Behavioral Glaucoma II: Influence of Insurance on Physician Prescribing Practices (ASCRS-ASOA 2023) - "Purpose A recent survey of WI ophthalmologists showed that therapeutic decisions might not be purely logical.Specifically, reluctance to use newer medications and to remove non visually significant cataracts for angle closure glaucoma.This study seeks to understand the role of insurance reimbursement and policy in these decisions.MethodsWe researched publicly available information to compare the price and ease of access of Latanoprost and Rocklatan in a hypothetical patient under multiple insurance scenarios.We also assessed Medicare coverage of cataract removal to treat angle closure glaucoma.ResultsThe average retail cost of Latanoprost for an uninsured patient was $8.62, while Rocklatan was $337.61.There was an evident cost benefit to insurance coverage, however this was difficult to quantify due to preauthorization requirements and other factors.This complexity itself may deter use of newer medications.Cataract surgery has been shown to be safe and effective in the..."

Reimbursement • US reimbursement • Cataract • Glaucoma • Ophthalmology

Rocklatan® Evaluation (clinicaltrials.gov) - P4 | N=136 | Active, not recruiting | Sponsor: Aerie Pharmaceuticals | Recruiting ➔ Active, not recruiting

Enrollment closed • Cardiovascular • Glaucoma • Ophthalmology

Extreme intraocular pressure and steroid-dependent iritis. (PubMed, J Cataract Refract Surg) - "The patient was referred when the IOP measured 44 mm Hg in the left eye despite aggressive medical therapy, including acetazolamide...Current medications in the left eye include brimonidine 3 times a day, loteprednol 2 times a day, nepafenac 2 times a day, and fixed combination latanoprost + netarsudil at bedtime. Her only medication in the right eye was travoprost. She is intolerant to dorzolamide...Visual field was normal in both eyes (Figures 1 and 2). Optical coherence tomography of retinal nerve fiber layer (RNFL) is shown in Figure 3 and retinal ganglion cell layer is shown in Supplemental Figure 1 (http://links.lww.com/JRS/A756).JOURNAL/jcrs/04.03/02158034-202301000-00020/figure1/v/2022-12-26T045736Z/r/image-tiffJOURNAL/jcrs/04.03/02158034-202301000-00020/figure2/v/2022-12-26T045736Z/r/image-tiffJOURNAL/jcrs/04.03/02158034-202301000-00020/figure3/v/2022-12-26T045736Z/r/image-tiff Please comment on your management of this patient's left eye."

Journal • Cataract • Idiopathic Arthritis • Immunology • Inflammation • Inflammatory Arthritis • Macular Edema • Ocular Inflammation • Ophthalmology • Rheumatoid Arthritis • Rheumatology • Uveitis

A novel fixed-combination timolol-netarsudil-latanoprost ophthalmic solution for the treatment of glaucoma and ocular hypertension. (PubMed, Asian J Pharm Sci) - "Importantly, once-daily FC-TNL exerted potent IOP-lowering effect and protective effect on retinal ganglion cells. The FC-TNL was stable, safe and effective, being a promising glaucoma therapeutic."

Journal • Cardiovascular • Glaucoma • Ophthalmology

"Adding Rocklatan, Rhopressa, and potentially more through the transaction:" (@DrMariaCT)

A Deep Learning–Based Smartphone Application Increases Patient's Medication Identification Speed and Accuracy: A Clinical Case Series (AAO 2022) - "Here, we expanded the model's database and tested its effectiveness with patients from an academic glaucoma clinic. An iOS app-embedded CNN (MobileNetV3) was trained with 9860 images and tested on 1088 images of 8 medications: Pred Forte, Vigamox, Rocklatan, Rhopressa, Xalatan, Trusopt, Combigan, and Alphagan. Utilization of an iOS application integrated with MobileNetV3 architecture is a promising tool to help visually-impaired patients quickly and accurately identify their ophthalmic medication bottles."

Clinical • Glaucoma • Ophthalmology

Comparison of netarsudil/latanoprost therapy with latanoprost monotherapy for lowering intraocular pressure: a systematic review and meta-analysis. (PubMed, Korean J Ophthalmol) - "The symptoms of CH were mostly mild, and only a few glaucoma patients discontinued the medication owing to CH in earlier clinical trials. Therefore, it would be beneficial to consider the administration of netarsudil/latanoprost FDC therapy in patients with glaucoma."

Journal • Monotherapy • Retrospective data • Review • Glaucoma • Ophthalmology

Efficacy and safety of netarsudil/latanoprost fixed-dose combination vs. monotherapy in open-angle glaucoma or ocular hypertension: A systematic review and meta-analysis of randomized controlled trials. (PubMed, Front Med (Lausanne)) - "However, there are concerns that netarsudil/latanoprost FDC was associated with a significantly higher incidence of AEs specifically compared with latanoprost. https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=311956."

Monotherapy • Retrospective data • Review • Cardiovascular • Glaucoma • Ophthalmology

The effectiveness and tolerability of fixed-dose combination netarsudil 0.02%/latanoprost 0.005% at a tertiary glaucoma center. (PubMed, Graefes Arch Clin Exp Ophthalmol) - "FCNL was well-tolerated and demonstrated a significant and sustained reduction in IOP, even as last-line therapy before incisional or laser surgery in those on maximum glaucoma pharmacotherapy. FCNL is a viable treatment option for glaucomatous eyes before consideration of surgical intervention."

Journal • Allergy • Glaucoma • Immunology • Ophthalmology